SynthesisBrain and behavior2026
Impact of Modifiable Cardiovascular Risk Factors and Protective Therapies on Hemorrhagic Events in Cerebral Cavernous Malformations: A Systematic Review and Meta-Analysis.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCerebral cavernous malformations (CCM) are vascular lesions prone to hemorrhage, but the influence of modifiable cardiovascular risk factors and commonly prescribed therapies on bleeding risk remains unclear.
methodsWe performed a systematic review and meta-analysis according to PRISMA 2020. PubMed/MEDLINE, Embase, and Scopus were searched from inception through August 31, 2025. Eligible observational studies and randomized trials reported adults with CCM stratified by modifiable cardiovascular risk factors or systemic therapies. Hemorrhagic presentation at diagnosis and prospective symptomatic hemorrhage or rebleeding during follow-up were extracted and interpreted as distinct clinical endpoints. Comparable adjusted and crude estimates were pooled separately using random-effects models; randomized trials with non-comparable populations or endpoints were summarized narratively. Risk of bias and certainty of evidence were assessed using design-appropriate Cochrane tools and GRADE, respectively.
resultsOf 1275 records identified, 30 full texts were reviewed, and 22 studies met inclusion criteria, comprising 7331 patients with CCM. Most pooled analyses evaluated hemorrhagic presentation at diagnosis. Smoking was associated with increased odds of hemorrhagic presentation (aOR 1.41, 95% CI 1.03-1.93), and obesity showed an uncertain signal toward higher odds (aOR 1.77, 95% CI 1.00-3.13). Antithrombotic therapy was associated with lower odds of hemorrhagic presentation (aOR 0.46, 95% CI 0.29-0.73), while statins showed a nonsignificant association (aOR 0.79, 95% CI 0.52-1.20). Randomized propranolol and atorvastatin trials were considered separately because their prospective endpoints and trial populations were not directly comparable with the observational presentation-based analyses.
conclusionsEvidence regarding systemic cardiovascular factors and therapies in CCM remains sparse and predominantly of low or very low certainty. The observed associations are preliminary, may reflect residual confounding and treatment-selection bias, and should not be interpreted as causal or as direct estimates of future hemorrhage risk. Prospective multicenter studies with standardized clinical and imaging definitions are needed before these findings can inform treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.